輸液セットの世界市場-2023-2030

市場概要

輸液セットは、インスリンポンプ送達デバイスを身体に接続します。輸液セットは、インスリンポンプと体内をつなぐもので、静脈ラインと同じように操作します。注射針は、通常、皮下脂肪の皮膚の下に置かれる小さなプラスチック製のチューブであるカニューレの中に留置されます。この針は、セットを挿入するために皮膚に穴を開けるために必要です。

市場力学

糖尿病患者数の増加、市場の開拓、糖尿病対策におけるさまざまな機関の取り組みの増加が、予測期間を通じて輸液セットの世界市場の成長を後押ししています。

糖尿病患者の増加や市場開拓の進展が、予測期間中の輸液セットの世界市場を押し上げます。

世界的に糖尿病の優勢が高まっていることは、世界市場の成長を促進しています。例えば、国際糖尿病連盟によると、2021年には5億3,700万人以上の成人が糖尿病を患っており、世界では10人に1人が糖尿病を患っているとされています。2030年には6億4,300万人、2045年には7億8,300万人に増加すると推測されています。また、成人の糖尿病患者の4人に3人は、低・中所得国にいます。2021年には、糖尿病が原因で5秒に1人が死亡し、世界全体の死亡者数は670万人以上となりました。2021年の世界全体の糖尿病ヘルスケア支出は約9660億米ドルで、過去15年間で316％増加しています。

2億4000万人以上の糖尿病患者が診断されておらず、5億4100万人以上の成人が2型糖尿病を発症しかけており、約2100万人の出生児が妊娠中に糖尿病の影響を受けています。さらに、市場の開拓が進んでいることも、予測期間中の世界市場の成長に寄与しています。例えば、2022年11月、ヘルスケア技術の世界的リーダーであるメドトロニックplcは、最大7日間の装着にタグ付けされた最初で唯一の輸液セット「Medtronic Extended infusion set」を米国で発売すると発表しています。輸液セットは、インスリンポンプから体内にインスリンを移送するチューブで、通常、2～3日ごとにセット交換が必要です。また、2022年1月、米国食品医薬品局（FDA）は、キャピラリーバイオメディカル（CapBio）がSteudiFlow 7日間装着型輸液セット技術の主要試験を開始するための治験機器適用除外（IDE）を承認しました。

製品リコールが世界市場の成長を阻害しています。

しかし、多くの輸液ポンプ製品のリコールが予測期間中の市場成長を妨げると予測されます。例えば、2020年3月、米国食品医薬品局は、Becton Dickinson Alaris System輸液ポンプのリコールを、重傷または死亡を引き起こす可能性のある医療機器に対する同局の最も厳しいリコールであるクラスIに分類したと発表しています。

COVID-19の影響分析

COVID-19の発生は、世界の輸液セット市場の成長にプラスの影響を与えると予想されます。例えば、2020年5月、米国食品医薬品局（FDA）は、COVID-19感染症による障害の治療に医療従事者が利用する輸液ポンプおよび付属品の包括的な緊急使用承認を割り当てました。米国FDAはEUA（緊急使用許可証）を発行し、輸液ポンプの入手性を向上させました。したがって、COVID-19の大流行時の輸液ポンプ使用の増加は、輸液ポンプと付属品の生産を押し上げ、予測期間中の輸液セット市場を押し上げると予測されます。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 市場イベント
    • 糖尿病患者の増加
  • 抑制要因
    • 製品回収
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 タイプ別

• フィルターあり
• フィルターなし

第8章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療施設
• ASC

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第11章 企業プロファイル

• Medtronic Plc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Tandem Diabetes
• Micsafe Medical
• Fresenius Kabi
• Smith Medical
• Becton, Dickinson and Company（BD）
• B. Braun Melsungen AG
• Baxter
• Bexen Medical
• Wuhan W.E.O Science & Technology

第12章 DataM

Market Overview

The global infusion sets size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

An infusion set links the insulin pump delivery device to the body. It operates the exact way an intravenous line does. A needle is lodged inside a cannula, a tiny plastic tube normally placed under the skin in the subcutaneous fat. This needle is required to puncture the skin to insert the set.

Market Dynamics

The rising number of diabetes patients, the growing market developments and increasing initiatives by various bodies in the fight against diabetes are boosting the global infusion set market growth throughout the forecast period.

The rising cases of diabetes and growing market developents boost the global infusion set market in the forecast period.

The growing preponderance of diabetes globally is driving the global market growth. For instance, according to the International Diabetes Federation, in 2021, over 537 million adults had diabetes, making it 1 out of 10 people globally. It is estimated to rise to 643 million by 2030 and 783 million by 2045. Also, 3 in 4 adults with diabetes are in low- and middle-income countries. In 2021 diabetes caused one death every five seconds accounting for over 6.7 million deaths globally. Globally diabetes healthcare expenditure for 2021 was around $ 966 billion accounting for a 316% rise over the last 15 years.

More than 240 million cases of diabetes are undiagnosed, over 541 million adults are on the verge of developing type 2 diabetes, and around 21 million live births are affected with diabetes during pregnancy. Furthermore, the growing market developments also contribute to the global market growth during the forecast period. For instance, in November 2022, Medtronic plc, a global leader in healthcare technology, announced the U.S. launch of the Medtronic Extended infusion set, the first and only infusion set tagged for up to 7-day wear. An infusion set is tubing that transfers insulin from an insulin pump to the body and typically requires a set change every two to three days. Also, in January 2022, The U.S. Food and Drug Administration (FDA) approved the investigational device exemption (IDE) for Capillary Biomedical (CapBio) to initiate a key trial of its SteadiFlow seven-day-wear infusion set technology.

The product recalls hinders the global market growth.

However, many infusion pump product recalls are predicted to hamper the market growth during the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration announced that it had classified the Becton Dickinson Alaris System infusion pump recall as a Class I recall, the agency's most severe recall for medical devices that could cause serious injury or death.

COVID-19 Impact Analysis

The COVID-19 outbreak is anticipated to impact the global infusion set market's growth positively. For example, in May 2020, The U.S. Food and Drug Administration (FDA) allocated an umbrella emergency use approval for infusion pumps and accessories to be utilized by healthcare professionals to treat disorders caused by the COVID-19 infection. The U.S. FDA issued EUAs (Emergency Use Authorizations) that have improved the availability of infusion pumps. Therefore, the rise in infusion pump use during the COVID-19 pandemic has boosted the production of infusion pumps and accessories, which is predicted to push the infusion set market during the forecast period.

Segment Analysis

Infusion sets with filters are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

Infusion filters are employed to reliably control particles from penetrating the human body, averting life-threatening blood clots, or dispersing drugs in a specific and steady pattern. The filtration/retention rate can be determined by choosing the correct pore size. By choosing the most suitable pore size, the retention rate for undersized particles can be decided, and the flow rate for the infusion solution be selected by correlating the membrane flow rate with the priming pressure of the drug delivery solution. Also, the availability of various filters ensures the dominance of the infusion sets with filter segment dominance in the forecast period. For example, the nucleopore membrane precise filtering infusion set can effectively intercept particles and play the role of filtering particles, significantly reducing the pain caused by infusion, effectively reducing the infusion reaction, and ensuring infusion safety. Also, the track-etched membranes have a highly defined pore structure and adjustable pore size and flow parameters. They can offer a unique solution for every infusion filter application. In addition, mounting can be done conveniently with ultrasonic welding or other assembly methods. These track-etched membranes come in pore sizes of 0.1 µm up to 10.0 µm and possess irradiation stability towards Gamma and X-ray for very convenient sterilization of the whole unit. Thus, the mentioned data indicates that the infusion set with filter holds most of the global infusion set market in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

The increasing cases of diabetes in North America contribute to the dominance of this region over the global market throughout the forecast period (2022-20292); for instance, the data from the American International Diabetes Federation indicates that in 2021 in North America and the Caribbean, there were 51 million adults living with diabetes which is predicted to be 57 million by 2030 and 63 million by 2045. Also, around 1 out of 4 American adults had diabetes but were undiagnosed. In 2021 diabetes claimed over 931,000 deaths and a total of $ 415 billion expenditure for diabetes. Furthermore, the increasing government initiatives to fight against diabetes also contribute to North America's dominance over the global infusion set market throughout the forecast period. For instance, in 2021, the Government of Canada announced $35 million for investments in diabetes, specifically, $25 million for diabetes research, surveillance, and prevention, as well as the development of a national framework for diabetes.

Also, expand access to the National Diabetes Prevention Program's (National DPP) lifestyle change program, an evidence-based intervention to prevent or delay the onset of type 2 diabetes in adults at high risk. The year-long program uses a CDC-approved curriculum, is facilitated by a trained lifestyle coach, and focuses on making realistic behavior changes through healthy eating, increasing physical activity, and managing stress. Thus, owing to the data mentioned the North American infusion set market is estimated to grow at a high CAGR throughout5 the forecast period.

Competitive Landscape

The growing cases of diabetes keep the global infusion sets the market competitive. Micsafe Medical, Fresenius Kabi, Smith Medical, Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Baxter, Tandem Diabetes, Bexen Medical, and Wuhan W.E.O Science & Technology are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in July 2022, Tandem Diabetes Care acquired infusion set developer Capillary Biomedical.

Medtronic Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic plc has a MiniMed Mio Advance infusion set: This has a 90° soft cannula and can be inserted with only four steps. The all-in-one insertion design means that no separate serter is required.

The global infusion sets market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Market Events
    • 4.1.1.2. The Growing Cases of Diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. Product Recalls
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. With Filter *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Without Filter

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Specialty Clinics
• 8.4. Homecare Settings
• 8.5. ASCs

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking

11. Company Profiles

• 11.1. Medtronic Plc.
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Tandem Diabetes
• 11.3. Micsafe Medical
• 11.4. Fresenius Kabi
• 11.5. Smith Medical
• 11.6. Becton, Dickinson and Company (BD)
• 11.7. B. Braun Melsungen AG
• 11.8. Baxter
• 11.9. Bexen Medical
• 11.10. Wuhan W.E.O Science & Technology

LIST NOT EXHAUSTIVE

12. DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us